Petrelintide Shows Promise in Phase 2 Trial for Weight Loss & Beyond

A new investigational drug, petrelintide, is showing promising results in the treatment of obesity and overweight, with trial participants experiencing up to 10.7% mean body weight reduction at 42 weeks, compared to 1.7% in the placebo group. The findings, released this month by Roche, suggest a potential new avenue for chronic weight management, particularly for those who may not respond adequately to existing therapies like GLP-1 receptor agonists.

The Phase II ZUPREME-1 trial, involving 493 participants with a mean BMI of 37 kg/m², evaluated the efficacy and safety of once-weekly subcutaneous injections of petrelintide. The study, designed as a dose-ranging trial, demonstrated statistically significant weight loss across all five treatment arms compared to placebo after 28 weeks, with the benefits sustained through week 42. Notably, the drug exhibited a favorable tolerability profile, with no reported cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events – a common challenge with many weight loss medications. Roche’s press release details these topline results.

Beyond Weight Loss: How Petrelintide Works

Petrelintide is an amylin analog, meaning it mimics the effects of amylin, a hormone naturally produced by the pancreas alongside insulin. Unlike incretins, which are the target of GLP-1 and GLP-1/GIP receptor agonists, amylin acts as an insulin sensitizer. In other words it helps the body use insulin more effectively, potentially improving blood sugar control. Dr. Donna H. Ryan, Professor Emerita at the Pennington Biomedical Research Center, highlights that the drug’s tolerability is particularly encouraging, suggesting it could be a valuable option for individuals who struggle with the side effects of other weight loss medications.

However, amylin’s potential benefits extend beyond glucose metabolism. Researchers are exploring its role in modulating metabolic adaptation during weight loss and its potential to address issues like amyloid deposition, which has been linked to Alzheimer’s disease and diabetic nephropathy. The unique design of petrelintide aims to prevent fibrillate formation, a characteristic of natural amylin associated with beta-cell failure. Its dual action on the calcitonin receptor may offer benefits for older adults at risk of osteoporosis. Details of the ZUPREME trial are available on ClinicalTrials.gov.

Gender Differences and Tolerability

An interesting observation from the ZUPREME-1 trial was the disparity in weight loss between male and female participants. Women in the study lost considerably more weight than men, a finding that warrants further investigation. Researchers will demand to determine whether this difference is due to biological factors, hormonal influences, or other variables.

The high tolerability of petrelintide is a key differentiator. In the cohort achieving the greatest weight reduction, 98% of participants reached the maintenance dose, underscoring the drug’s favorable safety profile. This is particularly significant given that gastrointestinal side effects are a common reason for discontinuation with other weight loss medications. The absence of vomiting and treatment discontinuations due to adverse events is a notable achievement.

Amylin Analogs in a Crowded Field

Petrelintide is entering a rapidly evolving landscape of obesity treatments. Pharmaceutical companies are increasingly focused on amylin and amylin/calcitonin analogs as the “next big thing” in addressing adiposity-based chronic diseases. While other amylin analogs in development also appear to have milder gastrointestinal side effects, some have reported fatigue as a potential side effect, a symptom that requires further study.

The ZUPREME-1 trial represents the first step in the regulatory process for petrelintide. While the initial signals are promising, further research and longer-term studies are needed to confirm its efficacy and safety. The drug’s potential to not only provide an alternative for those who don’t respond to GLP-1 therapies but also to offer novel disease-modifying characteristics makes it a compelling candidate in the fight against obesity.

What’s Next for Petrelintide?

The positive results from the ZUPREME-1 trial pave the way for further development of petrelintide, both as a monotherapy for chronic weight management and as a potential combination partner with other weight loss drugs. Roche will likely initiate larger, Phase III clinical trials to confirm these findings and gather more comprehensive safety data. Regulatory submissions to health authorities, such as the FDA in the United States and the EMA in Europe, will follow successful Phase III trials. The timeline for potential market availability remains uncertain, but the current momentum suggests that petrelintide could grow a valuable addition to the arsenal of tools available to combat obesity in the coming years. Healio provides additional coverage of the trial results and expert commentary.